瑛泰医疗(01501.HK)间接收购上海袤熠100%合伙权益总对价约3.74亿元

中金财经

Jul 23

　　格隆汇7月23日丨瑛泰医疗(01501.HK)公告，于2026年7月23日，公司及其指定全资子公司(即受让人)与上海袤熠若干现有合伙人(红杉保慧、红杉悦辰及太嘉杉)订立合伙权益转让协议，据此，转让人已同意转让，而受让人已同意境内间接收购上海袤熠100%合伙权益，总对价约人民币3.74亿元。上海袤熠间接持有目标公司Valgen Holding Corporation579,866股B轮优先股，占目标公司Valgen Holding Corporation已发行股本总额约3.85%。　　目标公司为Valgen Holding Corporation，乃一家根据开曼群岛法律注册成立并存续的获豁免公司，其持有德晋医疗100%股权。目标公司为无实质业务活动的控股公司。德晋医疗主要从事房室瓣疾病方面(尤其是二尖瓣及三尖瓣介入治疗)介入治疗技术及产品的研发、生产及销售。德晋医疗为目标集团在中国的主要经营实体。　　董事会认为，收购目标公司股权为公司提供补充其结构性心脏病领域产品管线机会，以实现该领域更全面产品覆盖，并提升集团于心血管介入领域整体竞争力及长远发展潜力。第三次收购事项旨在落实公司逐步增持目标公司股权策略。合伙权益转让协议项下交易架构，与公司向现有投资者收购目标公司股权的方针大致相符，亦与先前所披露经目标公司股东批准收购方案保持一致。　　

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2653040729"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653040729\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653040729?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-07-23 22:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653040729","market":"hk","top_or_hot":-1,"title":"瑛泰医疗(01501.HK)间接收购上海袤熠100%合伙权益 总对价约3.74亿元","media":"中金财经","content":"<html><body><p>　　格隆汇7月23日丨<a href=\"https://laohu8.com/S/01501\">瑛泰医疗</a>(01501.HK)公告，于2026年7月23日，公司及其指定全资子公司(即受让人)与上海袤熠若干现有合伙人(红杉保慧、红杉悦辰及太嘉杉)订立合伙权益转让协议，据此，转让人已同意转让，而受让人已同意境内间接收购上海袤熠100%合伙权益，总对价约人民币3.74亿元。上海袤熠间接持有目标公司Valgen Holding Corporation579,866股B轮优先股，占目标公司Valgen Holding Corporation已发行股本总额约3.85%。\r\n\r\n　　目标公司为Valgen Holding Corporation，乃一家根据开曼群岛法律注册成立并存续的获豁免公司，其持有德晋医疗100%股权。目标公司为无实质业务活动的控股公司。德晋医疗主要从事房室瓣疾病方面(尤其是二尖瓣及三尖瓣介入治疗)介入治疗技术及产品的研发、生产及销售。德晋医疗为目标集团在中国的主要经营实体。\r\n\r\n　　董事会认为，收购目标公司股权为公司提供补充其结构性心脏病领域产品管线机会，以实现该领域更全面产品覆盖，并提升集团于心血管介入领域整体竞争力及长远发展潜力。第三次收购事项旨在落实公司逐步增持目标公司股权策略。合伙权益转让协议项下交易架构，与公司向现有投资者收购目标公司股权的方针大致相符，亦与先前所披露经目标公司股东批准收购方案保持一致。\r\n\r\n　　 </p></body></html>","source":"zhongjincaijing_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>瑛泰医疗(01501.HK)间接收购上海袤熠100%合伙权益 总对价约3.74亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n瑛泰医疗(01501.HK)间接收购上海袤熠100%合伙权益 总对价约3.74亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-23 22:57 北京时间&nbsp;&nbsp;&nbsp;<a href=http://sc.stock.cnfol.com/gushizhibo/20260723/32316346.shtml><strong>中金财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇7月23日丨瑛泰医疗(01501.HK)公告，于2026年7月23日，公司及其指定全资子公司(即受让人)与上海袤熠若干现有合伙人(红杉保慧、红杉悦辰及太嘉杉)订立合伙权益转让协议，据此，转让人已同意转让，而受让人已同意境内间接收购上海袤熠100%合伙权益，总对价约人民币3.74亿元。上海袤熠间接持有目标公司Valgen Holding Corporation579,866股B轮优先股，占目标...</p>\n\n<a href=\"http://sc.stock.cnfol.com/gushizhibo/20260723/32316346.shtml\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01501","symbol_name":"瑛泰医疗","start_time":0,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260723/32316346.shtml","article_id":"2653040729","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653040729","pubTimestamp":1784818623,"columns":[],"sourceInfo":{"source_id":"zhongjincaijing_highlight","name":"中金在线"},"weMediaInfo":null,"summary":"格隆汇7月23日丨瑛泰医疗公告，于2026年7月23日，公司及其指定全资子公司与上海袤熠若干现有合伙人订立合伙权益转让协议，据此，转让人已同意转让，而受让人已同意境内间接收购上海袤熠100%合伙权益，总对价约人民币3.74亿元。上海袤熠间接持有目标公司Valgen Holding Corporation579,866股B轮优先股，占目标公司Valgen Holding Corporation已发行股本总额约3.85%。　　目标公司为Valgen Holding Corporation，乃一家根据开曼群岛法律注册成立并存续的获豁免公司，其持有德晋医疗100%股权。","collect":0,"end_time":0,"defaultTopTitle":"cnfol.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01501":"瑛泰医疗","BK1222":"医疗保健用品"},"translate_title":"Yingtai Medical (01501.HK) indirectly acquired 100% partnership interest in Shanghai Miao Yi for a total consideration of approximately 374 million yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01501":1.5},"content_text":"格隆汇7月23日丨瑛泰医疗(01501.HK)公告，于2026年7月23日，公司及其指定全资子公司(即受让人)与上海袤熠若干现有合伙人(红杉保慧、红杉悦辰及太嘉杉)订立合伙权益转让协议，据此，转让人已同意转让，而受让人已同意境内间接收购上海袤熠100%合伙权益，总对价约人民币3.74亿元。上海袤熠间接持有目标公司Valgen Holding Corporation579,866股B轮优先股，占目标公司Valgen Holding Corporation已发行股本总额约3.85%。\n\n　　目标公司为Valgen Holding Corporation，乃一家根据开曼群岛法律注册成立并存续的获豁免公司，其持有德晋医疗100%股权。目标公司为无实质业务活动的控股公司。德晋医疗主要从事房室瓣疾病方面(尤其是二尖瓣及三尖瓣介入治疗)介入治疗技术及产品的研发、生产及销售。德晋医疗为目标集团在中国的主要经营实体。\n\n　　董事会认为，收购目标公司股权为公司提供补充其结构性心脏病领域产品管线机会，以实现该领域更全面产品覆盖，并提升集团于心血管介入领域整体竞争力及长远发展潜力。第三次收购事项旨在落实公司逐步增持目标公司股权策略。合伙权益转让协议项下交易架构，与公司向现有投资者收购目标公司股权的方针大致相符，亦与先前所披露经目标公司股东批准收购方案保持一致。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}